CN113679689B - 用于纳米粒冷冻干燥物形式的组合物及方法 - Google Patents

用于纳米粒冷冻干燥物形式的组合物及方法 Download PDF

Info

Publication number
CN113679689B
CN113679689B CN202110916430.8A CN202110916430A CN113679689B CN 113679689 B CN113679689 B CN 113679689B CN 202110916430 A CN202110916430 A CN 202110916430A CN 113679689 B CN113679689 B CN 113679689B
Authority
CN
China
Prior art keywords
compound
cyclodextrin
nucleic acid
composition
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN202110916430.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113679689A (zh
Inventor
应文斌
R·阿达米
王宇伟
尹海清
王莉萍
刘�东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Priority to CN202110916430.8A priority Critical patent/CN113679689B/zh
Publication of CN113679689A publication Critical patent/CN113679689A/zh
Application granted granted Critical
Publication of CN113679689B publication Critical patent/CN113679689B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202110916430.8A 2015-07-22 2016-07-22 用于纳米粒冷冻干燥物形式的组合物及方法 Expired - Fee Related CN113679689B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110916430.8A CN113679689B (zh) 2015-07-22 2016-07-22 用于纳米粒冷冻干燥物形式的组合物及方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
US62/195,356 2015-07-22
CN202110916430.8A CN113679689B (zh) 2015-07-22 2016-07-22 用于纳米粒冷冻干燥物形式的组合物及方法
PCT/US2016/043537 WO2017015552A1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms
CN201680054543.9A CN108024957B (zh) 2015-07-22 2016-07-22 用于纳米粒冷冻干燥物形式的组合物及方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680054543.9A Division CN108024957B (zh) 2015-07-22 2016-07-22 用于纳米粒冷冻干燥物形式的组合物及方法

Publications (2)

Publication Number Publication Date
CN113679689A CN113679689A (zh) 2021-11-23
CN113679689B true CN113679689B (zh) 2023-09-01

Family

ID=57834582

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110916430.8A Expired - Fee Related CN113679689B (zh) 2015-07-22 2016-07-22 用于纳米粒冷冻干燥物形式的组合物及方法
CN201680054543.9A Expired - Fee Related CN108024957B (zh) 2015-07-22 2016-07-22 用于纳米粒冷冻干燥物形式的组合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680054543.9A Expired - Fee Related CN108024957B (zh) 2015-07-22 2016-07-22 用于纳米粒冷冻干燥物形式的组合物及方法

Country Status (23)

Country Link
US (3) US10300018B2 (enExample)
EP (1) EP3324932B1 (enExample)
JP (2) JP6875373B2 (enExample)
KR (1) KR102716928B1 (enExample)
CN (2) CN113679689B (enExample)
AU (1) AU2016297153B2 (enExample)
CA (1) CA2992849C (enExample)
CY (1) CY1123984T1 (enExample)
DK (1) DK3324932T3 (enExample)
EA (1) EA035761B1 (enExample)
ES (1) ES2862191T3 (enExample)
HR (1) HRP20210523T1 (enExample)
HU (1) HUE053990T2 (enExample)
IL (2) IL288342B2 (enExample)
LT (1) LT3324932T (enExample)
MX (1) MX373982B (enExample)
PL (1) PL3324932T3 (enExample)
PT (1) PT3324932T (enExample)
RS (1) RS61607B1 (enExample)
SI (1) SI3324932T1 (enExample)
SM (1) SMT202100196T1 (enExample)
TW (1) TWI732773B (enExample)
WO (1) WO2017015552A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113679689B (zh) * 2015-07-22 2023-09-01 日东电工株式会社 用于纳米粒冷冻干燥物形式的组合物及方法
US20210069121A1 (en) 2017-12-12 2021-03-11 Lead Biotherapeutics Ltd Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
US20210322575A1 (en) 2018-09-28 2021-10-21 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
EP4365289A3 (en) * 2018-11-16 2024-07-10 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
WO2021060440A1 (ja) * 2019-09-26 2021-04-01 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
CA3173554A1 (en) * 2020-02-28 2021-09-02 Microcures, Inc. Fidgetin-like 2 as a target to enhance wound healing
KR20230005244A (ko) * 2020-04-20 2023-01-09 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 생물학적 활성 건조 분말 조성물 및 이의 제조 및 사용 방법
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
US12458605B2 (en) 2020-10-02 2025-11-04 National University Corporation Hokkaido University Lipid nanoparticle
EP4416287A1 (en) 2021-10-14 2024-08-21 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
EP4426271B1 (en) * 2021-11-02 2025-07-23 Ziphius Nv Lipid nanoparticles for oligonucleotide delivery
KR102712873B1 (ko) * 2021-12-20 2024-10-04 고려자연식품(주) 과일향기 포집을 위한 나노 지질 전달체 제조와 분말화 방법
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
JP2025515480A (ja) * 2022-04-28 2025-05-15 カンザス、ステート、ユニバーシティ、リサーチ、ファウンデーション 封じ込める両親媒性ペプチドコロイド
US20240254485A1 (en) 2023-01-13 2024-08-01 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
EP4743061A1 (en) * 2023-07-13 2026-05-20 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof
CN121909225A (zh) 2023-09-27 2026-04-21 日油株式会社 用于核酸溶液的稳定剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102516417A (zh) * 2002-09-06 2012-06-27 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
CN103748078A (zh) * 2011-06-08 2014-04-23 夏尔人类遗传性治疗公司 可裂解脂质

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
PL1633327T3 (pl) 2003-06-04 2011-02-28 Univ Georgetown Sposób poprawienia stabilności i okresu trwałości kompleksów liposomowych
CA2584583A1 (en) 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
EP1811960A2 (en) * 2004-11-19 2007-08-01 Novosom AG Improvements in or relating to pharmaceutical compositions for local administration
EP2123288B1 (en) * 2007-02-09 2011-05-04 National University Corporation Nara Institute of Science and Technology C70 fullerene-containing liposome, method for producing the same, and use of the same
CN102811743B (zh) * 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
PT2768484T (pt) 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados
CA2853689C (en) 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
ES2557805T3 (es) 2012-03-28 2016-01-28 Discovery Laboratories, Inc. Liofilizacion de agente tensioactivo pulmonar liposomico sintetico
HK1206644A1 (en) * 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
TR201816986T4 (tr) 2012-06-08 2019-01-21 Nitto Denko Corp Terapötik ajan iletim formülasyonlarına yönelik lipitler.
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
CN113679689B (zh) * 2015-07-22 2023-09-01 日东电工株式会社 用于纳米粒冷冻干燥物形式的组合物及方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102516417A (zh) * 2002-09-06 2012-06-27 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
CN103748078A (zh) * 2011-06-08 2014-04-23 夏尔人类遗传性治疗公司 可裂解脂质

Also Published As

Publication number Publication date
US20240000710A1 (en) 2024-01-04
IL257029A (en) 2018-03-29
PT3324932T (pt) 2021-04-06
HRP20210523T1 (hr) 2021-05-14
DK3324932T3 (da) 2021-04-06
US12311055B2 (en) 2025-05-27
IL288342A (en) 2022-01-01
JP2021119161A (ja) 2021-08-12
JP2018521083A (ja) 2018-08-02
SMT202100196T1 (it) 2021-05-07
BR112018001178A2 (en) 2018-09-11
CN108024957B (zh) 2021-08-24
JP6875373B2 (ja) 2021-05-26
KR102716928B1 (ko) 2024-10-11
CN113679689A (zh) 2021-11-23
EA201890367A1 (ru) 2018-06-29
PL3324932T3 (pl) 2021-07-05
IL288342B2 (en) 2024-02-01
CY1123984T1 (el) 2022-05-27
HUE053990T2 (hu) 2021-08-30
AU2016297153A1 (en) 2018-03-01
CA2992849C (en) 2023-06-13
US11737982B2 (en) 2023-08-29
TWI732773B (zh) 2021-07-11
US20190231695A1 (en) 2019-08-01
EP3324932B1 (en) 2021-03-10
EP3324932A1 (en) 2018-05-30
MX2018000891A (es) 2018-06-11
SI3324932T1 (sl) 2021-07-30
ES2862191T3 (es) 2021-10-07
IL288342B1 (en) 2023-10-01
CN108024957A (zh) 2018-05-11
US20170020819A1 (en) 2017-01-26
RS61607B1 (sr) 2021-04-29
LT3324932T (lt) 2021-04-26
EA035761B1 (ru) 2020-08-06
TW201717914A (zh) 2017-06-01
CA2992849A1 (en) 2017-01-26
IL257029B (en) 2021-12-01
WO2017015552A1 (en) 2017-01-26
EP3324932A4 (en) 2019-03-06
KR20180030698A (ko) 2018-03-23
AU2016297153B2 (en) 2021-02-25
JP7268079B2 (ja) 2023-05-02
MX373982B (es) 2020-07-15
US10300018B2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
US12311055B2 (en) Compositions and methods for nanoparticle lyophile forms
JP6220389B2 (ja) アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物
TWI355946B (en) Proliposomal and liposomal compositions of poorly
CN102421451B (zh) 苯达莫司汀环多糖组合物
US20050260260A1 (en) Liposome compositions for the delivery of macromolecules
CN113613632A (zh) 麻醉剂的稳定制剂和相关剂型
US20240141342A1 (en) Rna interference delivery formulation and methods for malignant tumors
EP3453390A1 (en) Polymerized drug-containing pharmaceutical composition
BR112018001178B1 (pt) Composição, processo de produção de liófilo sólido, liófilo sólido, processo de preparação de um medicamento, medicamento e processo de preparação de um medicamento de ácido nucleico
JP2022551311A (ja) 活性剤の沈殿物を含む送達系複合体および使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230901